However, Eli Lilly continued to dom

However, Eli Lilly continued to dominate the emerging human insulin
market in performing R&D, surpassing major milestones during the
period from 1980 to 1985 covered by the consent decree. Following the
initial production of human insulin through recombinant DNA techniques
in 1978, Lilly initiated clinical trials of its human insulin product, “Humalin,”
in the United States in 1980, and invested in additional research facilities.
In 1982, Lilly was rewarded for its efforts, receiving the first
FDA approval for human insulin in the United States. Eli Lilly was actually
more active in filing for patents during the five-year period of the
decree than it was during the previous and subsequent five years combined.

Hasil (Bahasa Indonesia) 2:

Namun, Eli Lilly terus mendominasi insulin manusia muncul
pasar dalam melakukan R & D, melebihi tonggak utama selama
periode 1980-1985 ditutupi oleh keputusan persetujuan. Setelah
produksi awal insulin manusia melalui teknik DNA rekombinan
pada tahun 1978, Lilly memulai uji klinis produk insulin manusia, "Humalin,"
di Amerika Serikat pada tahun 1980, dan diinvestasikan dalam fasilitas riset tambahan.
Pada tahun 1982, Lilly dihargai untuk perusahaan upaya, menerima pertama
persetujuan FDA untuk insulin manusia di Amerika Serikat. Eli Lilly sebenarnya
lebih aktif dalam mengajukan paten selama periode lima tahun dari
keputusan dari itu selama lima tahun sebelumnya dan selanjutnya digabungkan.